Daniel Driscoll, MD
Ophthalmology · Hilo, HINPI 1790970291
Payments from drug & device makers
Across 275 payments — averaging $77.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$12K
- Regeneron Healthcare Solutions, Inc.$2K
- AbbVie$2K
- Glaukos Corporation$1K
- Mallinckrodt Hospital Products Inc.$613
- Sight Sciences, Inc.$578
- plus $3K from 19 others
What the payments were for
- Consulting fees$2,76713%
- Travel & lodging$6,51130%
- Food & beverage$11,94256%
- Gifts$190%
- Entertainment$1711%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 104 | $11,610 |
| Regeneron Healthcare Solutions, Inc. | 5 | $2,326 |
| AbbVie(2 entities) | 42 | $1,929 |
| Glaukos Corporation | 21 | $1,349 |
| Mallinckrodt Hospital Products Inc. | 15 | $613 |
| Sight Sciences, Inc. | 10 | $578 |
| Tersera Therapeutics LLC | 1 | $545 |
| Amgen(2 entities) | 12 | $500 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 17 | $416 |
| Bausch & Lomb Americas Inc. | 10 | $324 |
| Genentech USA, Inc. | 10 | $295 |
| Dompe US, Inc. | 5 | $197 |
| Optos, Inc. | 4 | $171 |
| Sun Pharmaceutical Industries Inc. | 6 | $156 |
| Shire North American Group Inc | 2 | $94 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $64 |
| Ocular Therapeutix, Inc. | 1 | $50 |
| ANI Pharmaceuticals, Inc. | 1 | $32 |
| Tarsus Pharmaceuticals, Inc. | 1 | $27 |
| Coopervision Inc. | 1 | $27 |
| Coherus Oncology, Inc. | 1 | $26 |
| Sandoz | 1 | $23 |
| Oyster Point Pharma, Inc. | 1 | $23 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Iridex Corporation | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Clareon$7,153
- ARGOS$6,877
- Centurion$6,622
- EYLEA HD$2,172
- Hydrus Microstent$547
- XEN GLAUCOMA TREATMENT SYSTEM$448
- Unity$238
- iDoseTR$183
- Voyager DSLT$148
- OMNI$125
- TEPEZZA$125
- VYZULTA$122
- OMNI(R) SURGICAL SYSTEM (US)$111
- IACCESS$107
- iStent inject W$107
- iStent Trabecular Micro-Bypass System Model iS3$107
- ACTHAR$104
- iDose$102
How this compares
$21,411 in reported general payments places this provider in the 85th percentile of 120 ophthalmology providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 17 | $470,193 |
| EyleaAflibercept | 123 | $267,184 |
| VabysmoFaricimab-Svoa | 64 | $186,418 |
| BesivanceBesifloxacin Hcl | 752 | $167,184 |
| Bromfenac Sodium | 525 | $98,795 |
| ProlensaBromfenac Sodium | 203 | $71,723 |
| Prednisolone Acetate | 1,264 | $67,619 |
| RestasisCyclosporine | 64 | $61,028 |
| XiidraLifitegrast | 64 | $53,315 |
| Eylea HdAflibercept | 11 | $28,536 |
| VyzultaLatanoprostene Bunod | 58 | $26,060 |
| RhopressaNetarsudil Mesylate | 46 | $19,102 |
| Loteprednol Etabonate | 117 | $18,478 |
| CequaCyclosporine | 28 | $16,123 |
| MoxifloxacinMoxifloxacin Hcl | 437 | $15,002 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $197 | $470,19317 claims |
| Regeneron Healthcare Solutions, Inc.Eylea, Eylea Hd | $2,326 | $295,719134 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCBesivance, Prolensa, Loteprednol Etabonate, Lotemax | $416 | $261,2591,083 claims |
| Genentech USA, Inc.Vabysmo | $295 | $186,41864 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo | $324 | $87,730133 claims |
| AbbVieRestasis, Restasis Multidose, Combigan, Lumigan | $1,929 | $84,820112 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $156 | $16,12328 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $23 | $13,82920 claims |
| AlconSimbrinza | $11,610 | $4,86319 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 120 ophthalmology providers in Hawaii.
Other ophthalmology in Hilo
- Raymond WeeAiea$2.4M
- Gregg KokameAiea$1.1M
- Carlton YuenHonolulu$440K
- James LaiAiea$430K
- Neda NikpoorHonolulu$322K
- Alan FaulknerHonolulu$207K
- Michael BennettHonolulu$190K
- Sarah ReadAiea$169K
- Jeffrey PetersonHonolulu$85K
- Rupa WongHonolulu$72K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.